Maida I - Search Results

1

Analysis of Patients' Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis.

Nava FA, Mangia A, Riglietta M, Somaini L, Foschi FG, Claar E, Maida I, Ucciferri C, Frigerio F, Hernandez C, Dovizio M, Perrone V, Degli Esposti L, Puoti M. Nava FA, et al. Among authors: maida i. Ther Clin Risk Manag. 2023 Aug 4;19:645-656. doi: 10.2147/TCRM.S409134. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 37560130 Free PMC article.

2

Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?

Puoti M, Babudieri S, Rezza G, Viale P, Antonini MG, Maida I, Rossi S, Zanini B, Putzolu V, Fenu L, Baiguera C, Sassu S, Carosi G, Mura MS. Puoti M, et al. Among authors: maida i. Antivir Ther. 2004 Aug;9(4):627-30. Antivir Ther. 2004. PMID: 15456094

3

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M. Antonini MG, et al. Among authors: maida i. Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3. Infection. 2008. PMID: 18458815 Clinical Trial.

4

OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.

Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, Angarano G, Verucchi G, Pontali E, Capetti A, Raise E, Ravasio V, Maida I, Iannacone C, Caputo A, Puoti M. Carosi G, et al. Among authors: maida i. Antivir Ther. 2014;19(8):735-45. doi: 10.3851/IMP2757. Epub 2014 Feb 28. Antivir Ther. 2014. PMID: 24583976

5

Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.

Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M. Pontali E, et al. Among authors: maida i. Antivir Ther. 2015;20(1):39-48. doi: 10.3851/IMP2781. Epub 2014 May 15. Antivir Ther. 2015. PMID: 24831457 Clinical Trial.

6

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G. Nasta P, et al. Among authors: maida i. J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3. J Womens Health (Larchmt). 2015. PMID: 25682817

7

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744

8

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758

9

Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.

Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Di Maio VC, et al. Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. Liver Int. 2021. PMID: 33497016

10

Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free.

Fiore V, De Vito A, Colpani A, Manca V, Maida I, Madeddu G, Babudieri S. Fiore V, et al. Among authors: maida i. Life (Basel). 2022 Nov 13;12(11):1873. doi: 10.3390/life12111873. Life (Basel). 2022. PMID: 36431008 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page